Nothing Special   »   [go: up one dir, main page]

FI955940A0 - Farmaseuttisesti aktiivisia CNS-yhdisteitä - Google Patents

Farmaseuttisesti aktiivisia CNS-yhdisteitä

Info

Publication number
FI955940A0
FI955940A0 FI955940A FI955940A FI955940A0 FI 955940 A0 FI955940 A0 FI 955940A0 FI 955940 A FI955940 A FI 955940A FI 955940 A FI955940 A FI 955940A FI 955940 A0 FI955940 A0 FI 955940A0
Authority
FI
Finland
Prior art keywords
pharmaceutically active
active cns
cns compounds
compounds
pharmaceutically
Prior art date
Application number
FI955940A
Other languages
English (en)
Swedish (sv)
Other versions
FI955940A (fi
Inventor
Alistair Ainslie Miller
Malcolm Stuart Nobbs
Richard Martin Hyde
Michael John Leach
Original Assignee
Wellcome Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB888828620A external-priority patent/GB8828620D0/en
Priority claimed from GB898908561A external-priority patent/GB8908561D0/en
Priority claimed from GB8918893A external-priority patent/GB8918893D0/en
Application filed by Wellcome Found filed Critical Wellcome Found
Priority to FI955940A priority Critical patent/FI955940A/fi
Publication of FI955940A0 publication Critical patent/FI955940A0/fi
Publication of FI955940A publication Critical patent/FI955940A/fi

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/56—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and doubly-bound oxygen atoms bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/56—One oxygen atom and one sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/58—Two sulfur atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
FI955940A 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä FI955940A (fi)

Priority Applications (1)

Application Number Priority Date Filing Date Title
FI955940A FI955940A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB888828620A GB8828620D0 (en) 1988-12-07 1988-12-07 Pharmaceutically active cns compounds
GB898908561A GB8908561D0 (en) 1989-04-14 1989-04-14 Pharmaceutically active cns compounds
GB8918893A GB8918893D0 (en) 1989-08-18 1989-08-18 Pharmacologically active cns compounds
FI895821A FI895821A0 (fi) 1988-12-07 1989-12-05 Farmaceutiskt aktiva cns foereningar.
FI955940A FI955940A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä

Publications (2)

Publication Number Publication Date
FI955940A0 true FI955940A0 (fi) 1995-12-11
FI955940A FI955940A (fi) 1995-12-11

Family

ID=27264228

Family Applications (4)

Application Number Title Priority Date Filing Date
FI895821A FI895821A0 (fi) 1988-12-07 1989-12-05 Farmaceutiskt aktiva cns foereningar.
FI955939A FI955939A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä
FI955941A FI955941A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä
FI955940A FI955940A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä

Family Applications Before (3)

Application Number Title Priority Date Filing Date
FI895821A FI895821A0 (fi) 1988-12-07 1989-12-05 Farmaceutiskt aktiva cns foereningar.
FI955939A FI955939A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä
FI955941A FI955941A (fi) 1988-12-07 1995-12-11 Farmaseuttisesti aktiivisia CNS-yhdisteitä

Country Status (36)

Country Link
US (7) US5587380A (fi)
EP (8) EP0727212A3 (fi)
JP (1) JP2795498B2 (fi)
KR (1) KR0145308B1 (fi)
CN (5) CN1052306A (fi)
AP (1) AP164A (fi)
AT (4) ATE384703T1 (fi)
AU (5) AU669929B2 (fi)
CA (2) CA2271566C (fi)
CY (1) CY2139B1 (fi)
DD (1) DD292250A5 (fi)
DE (4) DE68929554T2 (fi)
DK (2) DK175796B1 (fi)
ES (4) ES2095842T3 (fi)
FI (4) FI895821A0 (fi)
GE (1) GEP19970891B (fi)
GR (1) GR3022031T3 (fi)
HK (1) HK1004092A1 (fi)
HU (3) HUT55764A (fi)
IE (1) IE80711B1 (fi)
IL (7) IL92558A (fi)
LT (1) LT3415B (fi)
LV (1) LV10442B (fi)
MC (1) MC2076A1 (fi)
MX (1) MX9203422A (fi)
MY (1) MY115951A (fi)
NO (4) NO178926C (fi)
NZ (4) NZ260820A (fi)
OA (1) OA09148A (fi)
PH (1) PH31658A (fi)
PL (1) PL162957B1 (fi)
PT (1) PT92502B (fi)
RU (2) RU2121998C1 (fi)
SG (1) SG43314A1 (fi)
SK (2) SK279988B6 (fi)
UA (2) UA41245C2 (fi)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
US5629016A (en) * 1991-01-30 1997-05-13 Glaxo Wellcome Inc. Water-dispersible tablets
DK0522128T3 (da) * 1991-01-30 1996-02-26 Wellcome Found Vanddispergerbare tabletter indeholdende acyclovir
GB9215908D0 (en) * 1992-07-27 1992-09-09 Wellcome Found Water dispersible tablets
WO1994014780A1 (en) * 1992-12-18 1994-07-07 The Wellcome Foundation Limited Pyrimidine, pyridine, pteridinone and indazole derivatives as enzyme inhibitors
GB9226377D0 (en) * 1992-12-18 1993-02-10 Babbedge Rachel C Pharmaceutical compositions
US5698226A (en) * 1993-07-13 1997-12-16 Glaxo Wellcome Inc. Water-dispersible tablets
US5698695A (en) * 1993-09-10 1997-12-16 E. I. Du Pont De Nemours And Company Process for preparing 2-amino-4,6-dichloropyrimidine
GB9424766D0 (en) * 1994-12-07 1995-02-08 Wellcome Found Pharmaceutical composition
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
US6025355A (en) 1997-05-19 2000-02-15 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US6242198B1 (en) 1996-07-25 2001-06-05 Cambridge Neuroscience, Inc. Methods of treatment of eye trauma and disorders
US6756389B2 (en) 1996-08-09 2004-06-29 Cambridge Neuroscience, Inc. Pharmaceutically active compounds and methods of use
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
US6440965B1 (en) 1997-10-15 2002-08-27 Krenitsky Pharmaceuticals, Inc. Substituted pyrimidine derivatives, their preparation and their use in the treatment of neurodegenerative or neurological disorders of the central nervous system
IT1300056B1 (it) * 1998-04-17 2000-04-05 Boehringer Ingelheim Italia Eterocicli con anello a 6 termini difenil-sostituiti loro procedimento di preparazione e loro impiego come farmaci
US6420354B1 (en) 1998-06-08 2002-07-16 Advanced Medicine, Inc. Sodium channel drugs and uses
US6583148B1 (en) 1999-04-08 2003-06-24 Krenitsky Pharmaceuticals, Inc. Neurotrophic substituted pyrimidines
US6479498B1 (en) 1999-06-04 2002-11-12 Theravance, Inc. Sodium channel drugs and uses
AR029489A1 (es) * 2000-03-10 2003-07-02 Euro Celtique Sa Piridinas, pirimidinas, pirazinas, triazinas sustituidas por arilo, composiciones farmaceuticas y el uso de las mismas para la manufactura de un medicamento
AU2001273574A1 (en) 2000-07-24 2002-02-05 Krenitsky Pharmaceuticals Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
AR037233A1 (es) * 2001-09-07 2004-11-03 Euro Celtique Sa Piridinas aril sustituidas, composiciones farmaceuticas y el uso de dichos compuestos para la elaboracion de un medicamento
US7465735B2 (en) * 2001-11-19 2008-12-16 Basf Aktiengesellschaft 5-Phenypyrimidines their preparation compositions comprising them and their use
GB0300783D0 (en) * 2003-01-14 2003-02-12 Btg Int Ltd Treatment of neurodegenerative conditions
US8007826B2 (en) * 2003-12-11 2011-08-30 Acorda Therapeutics, Inc. Sustained release aminopyridine composition
US8354437B2 (en) * 2004-04-09 2013-01-15 Acorda Therapeutics, Inc. Method of using sustained release aminopyridine compositions
CA2562315A1 (en) 2004-05-19 2005-12-01 Basf Aktiengesellschaft 2-substituted pyrimidines and their use as pesticides
MX2007000428A (es) * 2004-07-15 2008-03-05 Amr Technology Inc Tetrahidroisoquinolinas sustituidas con arilo y heteroarilo y uso de las mismas para bloquear la captacion de norepinefrina, dopamina y serotonina.
GB0603087D0 (en) * 2006-02-15 2006-03-29 Glaxo Group Ltd Novel use
CN101641099A (zh) * 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
GB0800741D0 (en) 2008-01-16 2008-02-20 Univ Greenwich Cyclic triazo and diazo sodium channel blockers
WO2009123221A1 (ja) * 2008-03-31 2009-10-08 全薬工業株式会社 細胞保護作用を有するピリミジン誘導体およびその用途
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
CN101343253B (zh) * 2008-06-24 2011-03-16 陕西师范大学 2-氨基-4,5-二芳基嘧啶类化合物及其制备方法和药物用途
WO2010132487A1 (en) 2009-05-12 2010-11-18 Bristol-Myers Squibb Company CRYSTALLINE FORMS OF (S)-7-([1,2,4]TRIAZOLO[1,5-a]PYRIDIN-6-YL)-4-(3,4-DICHLOROHPHENYL)-1,2,3,4-TETRAHYDROISOQUINOLINE AND USE THEREOF
AU2010247849B2 (en) 2009-05-12 2015-11-19 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
GB201111712D0 (en) 2011-07-08 2011-08-24 Gosforth Ct Holdings Pty Ltd Pharmaceutical compositions
WO2013138787A1 (en) * 2012-03-16 2013-09-19 The Board Of Regents For Oklahoma State University Highly 6-substituted -2,4-diaminopyrimidines as inhibitors of anthrax
DE102013100799A1 (de) * 2012-12-21 2014-06-26 Endress + Hauser Flowtec Ag Umformerschaltung mit einer Stromschnittstelle sowie Meßgerät mit einer solchen Umformerschaltung
TWI644899B (zh) * 2013-02-04 2018-12-21 健生藥品公司 Ｆｌａｐ調節劑
EP2951170B1 (en) 2013-02-04 2018-10-24 Janssen Pharmaceutica NV Flap modulators
GB2560903A (en) 2017-03-27 2018-10-03 Azad Pharmaceutical Ingredients Ag New synthetic path to pharmaceutically acceptable vismodegib
GB202006076D0 (en) 2020-04-24 2020-06-10 Univ Greenwich Interleukin inhibitors
GB202006080D0 (en) 2020-04-24 2020-06-10 Univ Greenwich Cytokine storm syndrome

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA741825A (en) * 1966-08-30 Stenbuck Paul Propionitrile condensation intermediates
BE518622A (fi) *
US2624731A (en) * 1953-01-06 S-phenylpyrimidkn e x derivativesx
US2594309A (en) * 1952-04-29 Antimalarial agents and method of
US2576939A (en) * 1951-12-04 -diamino-s-phenyl-e-alkyl-
US2602794A (en) * 1952-07-08 Process for preparation of x-amino-s
CH207759A (de) * 1938-03-07 1939-11-30 Mayer & Schmidt Schleifmaschin Feinbohrspindel mit radial verschiebbarem Werkzeugträger.
GB691020A (en) * 1950-02-15 1953-05-06 Wellcome Found Improvements in or relating to pyrimidine derivatives of therapeutic value and to the manufacture thereof
GB715813A (en) * 1950-06-14 1954-09-22 Wellcome Found Improvements in derivatives of pyrimidine
US2688019A (en) * 1951-08-25 1954-08-31 Burroughs Wellcome Co 6-aryl-2,4-diamino pyrimidines and process of preparing same
DE956306C (de) * 1952-01-30 1957-01-17 Rhone Poulenc Sa Verfahren zur Herstellung von neuen Derivaten des Pyrimidins
DE951991C (de) * 1952-01-30 1956-11-08 Rhone Poulenc Sa Verfahren zur Herstellung von neuen chlorierten Derivaten des Pyrimidins
GB760944A (en) * 1952-11-04 1956-11-07 Wellcome Found Improvements in and relating to pyrimidine derivatives and their manufacture
DE1009188B (de) * 1953-05-21 1957-05-29 Rhone Poulenc Sa Verfahren zur Herstellung von Pyrimidinderivaten
DE1303727B (de) * 1959-09-03 1976-02-05 Ausscheidung aus: 14 45 176 The Wellcome Foundation Ltd., London Alpha-Arylidensubstituierte Propioni-Irile
US3980781A (en) * 1966-03-31 1976-09-14 Imperial Chemical Industries Limited Fungicidal composition and method containing 2-amino-pyrimidines
DE1670854B2 (de) * 1967-04-20 1977-04-28 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,4,6- trichlorpyrimidinen
US3956327A (en) * 1969-03-06 1976-05-11 Burroughs Wellcome Co. Method of preparing 2,4-diamino-5-benzyl pyrimidines
US4005204A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of neoplasms in the brain with diamino dichloroalkyl pyrimidine
US4006235A (en) * 1973-03-23 1977-02-01 Burroughs Wellcome Co. Treating CNS lymphoma
US4005203A (en) * 1973-03-23 1977-01-25 Burroughs Wellcome Co. Treatment of meningeal leukemia with diamino dichlorophenyl pyrimidine
CH591457A5 (fi) * 1973-11-08 1977-09-15 Hoffmann La Roche
US3940393A (en) * 1974-06-21 1976-02-24 American Home Products Corporation Synthesis of 2,6-diaminopyrimidines
FR2306697A1 (fr) * 1975-04-10 1976-11-05 Sogeras Nouvelles pyrimidines utilisables comme medicaments antidiabetiques et hypocholesterolemiants
GB1582245A (en) * 1976-06-09 1981-01-07 Wellcome Found Benzyl cyanoacetal derivatives and their conversion to pyrimidine derivatives
JPS5625169A (en) 1979-06-01 1981-03-10 Wellcome Found Triazine derivative
US4438267A (en) * 1980-11-11 1984-03-20 Daluge Susan M Monoheteroring compounds and their use
DE3174994D1 (de) * 1980-11-27 1986-08-28 Wellcome Found Antibacterial benzylpyrimidines
FR2503162A1 (fr) * 1981-04-07 1982-10-08 Pharmindustrie Nouveaux derives de piperazino-2 pyrimidine, procedes pour leur preparation et leur utilisation comme medicaments ou comme intermediaires pour la fabrication de medicaments
FR2535718A1 (fr) * 1982-11-09 1984-05-11 Sanofi Sa (piperazinyl-1)-2 pyrimidines, leurs sels, procede pour leur preparation et compositions pharmaceutiques en contenant
US4496549A (en) * 1983-01-17 1985-01-29 American Cyanamid Company Treatment of malaria with antibiotics
FR2539741A1 (fr) * 1983-01-21 1984-07-27 Sanofi Sa Composes a noyau heterocyclique diazote, leur procede de preparation et les medicaments, actifs sur le systeme nerveux central, qui en contiennent
DE3321969A1 (de) * 1983-06-18 1984-12-20 Troponwerke GmbH & Co KG, 5000 Köln 2-pyrimidinyl-1-piperazin-derivate, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
DE3411571A1 (de) * 1984-03-29 1985-10-10 Merck Patent Gmbh, 6100 Darmstadt Pyrimidine
FR2567518B1 (fr) * 1984-07-11 1987-11-13 Sanofi Sa Nouveaux composes a noyau heterocyclique azote, leur preparation et les medicaments qui en contiennent
US4725600A (en) * 1984-07-13 1988-02-16 Fujisawa Pharmaceutical Co., Ltd. Pyrimidine compounds having activity as a cardiotonic anti-hypertensive cerebrovascular vasodilator and anti-platelet aggregation agent
DE3752141T2 (de) * 1986-02-24 1998-03-26 Mitsui Petrochemical Ind Mittel zur behandlung von neuropathie
AR242678A1 (es) * 1986-03-05 1993-04-30 Gonzalez Jorge Alberto Mejoras en instrumentos musicales de cuerda de arco.
DE3620841A1 (de) * 1986-06-21 1987-12-23 Basf Ag 4-aminopyrimidinderivate
FR2602507B1 (fr) * 1986-08-08 1989-06-09 Sanofi Pharma Procede de preparation de diamino-2,4 benzyl-5 pyrimidines
JPH01308229A (ja) * 1988-02-23 1989-12-12 Glaxo Group Ltd 複素環誘導体
PT89780A (pt) * 1988-02-23 1989-10-04 Glaxo Group Ltd Processo para a preparacao de derivados da tetrahidroisoquinolina
FI895821A0 (fi) * 1988-12-07 1989-12-05 Wellcome Found Farmaceutiskt aktiva cns foereningar.
HU206337B (en) * 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
FR2642758B1 (fr) * 1989-02-09 1991-05-17 Esteve Labor Dr Derives de pyrimidine,2-(4-((alpha)-heteroaryl-(alpha) aryl-((alpha)-alkyl)-methoxy)-butyl)-1-piperazinyl), avec activite serotoninergique
US5136080A (en) * 1989-12-04 1992-08-04 Burroughs Wellcome Co. Nitrile compounds
GB9012316D0 (en) * 1990-06-01 1990-07-18 Wellcome Found Pharmacologically active cns compounds
WO1992002513A1 (en) * 1990-08-06 1992-02-20 Fujisawa Pharmaceutical Co., Ltd. Heterocyclic compounds

Also Published As

Publication number Publication date
ES2300513T3 (es) 2008-06-16
DK613289D0 (da) 1989-12-06
FI895821A0 (fi) 1989-12-05
SK689889A3 (en) 1999-06-11
LT3415B (en) 1995-09-25
JPH02202876A (ja) 1990-08-10
HK1004092A1 (en) 1998-11-13
NZ244880A (en) 1996-03-26
IL114335A (en) 2000-12-06
CN1119099A (zh) 1996-03-27
KR900009610A (ko) 1990-07-05
AU5195596A (en) 1996-07-04
NO304649B1 (no) 1999-01-25
OA09148A (en) 1991-10-31
NO178926C (no) 1996-07-03
AU4915493A (en) 1994-01-13
IL92558A (en) 1996-01-31
US5591746A (en) 1997-01-07
HU211974A9 (en) 1996-01-29
NO894887D0 (no) 1989-12-06
DK175796B1 (da) 2005-02-21
ES2250967T3 (es) 2006-04-16
EP1325916B1 (en) 2008-01-23
DE68927368D1 (de) 1996-11-28
PH31658A (en) 1999-01-12
CA2004747C (en) 2000-05-30
CA2004747A1 (en) 1990-06-07
EP0715851A3 (en) 1997-10-01
RU2079493C1 (ru) 1997-05-20
DE68929540D1 (de) 2005-12-01
EP1681058A3 (en) 2008-04-16
NZ244881A (en) 1996-03-26
NZ260820A (en) 1996-04-26
UA41245C2 (uk) 2001-09-17
SG43314A1 (en) 1997-10-17
DE68927368T2 (de) 1997-03-13
NZ231650A (en) 1996-03-26
AU639216B2 (en) 1993-07-22
MC2076A1 (fr) 1990-10-12
EP0372934A3 (en) 1992-07-15
US5684005A (en) 1997-11-04
EP1681058A2 (en) 2006-07-19
GR3022031T3 (en) 1997-03-31
AU4596489A (en) 1990-06-14
AU690443B2 (en) 1998-04-23
DE68929460T2 (de) 2003-12-24
FI955940A (fi) 1995-12-11
NO941211D0 (no) 1994-04-05
ATE235906T1 (de) 2003-04-15
NO954489D0 (no) 1995-11-08
DE68929540T2 (de) 2006-06-14
ES2194884T3 (es) 2003-12-01
EP0713703A2 (en) 1996-05-29
EP0372934A2 (en) 1990-06-13
MY115951A (en) 2003-10-31
CA2271566C (en) 2003-02-04
JP2795498B2 (ja) 1998-09-10
DE68929460D1 (de) 2003-05-08
ATE144422T1 (de) 1996-11-15
CA2271566A1 (en) 1990-06-07
EP0727212A3 (en) 1997-10-01
EP1325916A1 (en) 2003-07-09
HU211677A9 (en) 1995-12-28
EP0715851A2 (en) 1996-06-12
ATE384703T1 (de) 2008-02-15
FI955939A0 (fi) 1995-12-11
FI955939A (fi) 1995-12-11
DE68929554T2 (de) 2009-01-29
SK279988B6 (sk) 1999-06-11
CN1113487A (zh) 1995-12-20
AU5195296A (en) 1996-07-18
RU2121998C1 (ru) 1998-11-20
EP0727213A3 (en) 1997-09-10
US5597827A (en) 1997-01-28
ES2095842T3 (es) 1997-03-01
FI955941A0 (fi) 1995-12-11
IL114335A0 (en) 1995-10-31
PT92502A (pt) 1990-06-29
UA42885C2 (uk) 2001-11-15
CN1117046A (zh) 1996-02-21
ATE307585T1 (de) 2005-11-15
PL162957B1 (pl) 1994-01-31
PT92502B (pt) 1995-08-09
NO954489L (no) 1990-06-08
EP0715851B1 (en) 2003-04-02
EP0372934B1 (en) 1996-10-23
US5635507A (en) 1997-06-03
EP0727213A2 (en) 1996-08-21
NO954490L (no) 1990-06-08
EP0727213B9 (en) 2007-11-07
DE68929554D1 (de) 2008-03-13
DK175781B1 (da) 2005-02-21
HUT55764A (en) 1991-06-28
GEP19970891B (en) 1997-11-27
EP0713703A3 (en) 1997-10-01
MX9203422A (es) 1992-07-01
US5712276A (en) 1998-01-27
IL114040A0 (en) 1995-10-31
IL92558A0 (en) 1990-08-31
US5597828A (en) 1997-01-28
AU5195396A (en) 1996-07-04
IL111627A0 (en) 1995-01-24
LV10442A (lv) 1995-02-20
NO954490D0 (no) 1995-11-08
LTIP269A (en) 1994-10-25
CN1066719C (zh) 2001-06-06
NO178926B (no) 1996-03-25
CY2139B1 (en) 2002-06-21
SK32198A3 (en) 1999-06-11
EP0727214A3 (en) 1997-10-01
AU669929B2 (en) 1996-06-27
EP0727213B1 (en) 2005-10-26
NO894887L (no) 1990-06-08
SK279977B6 (sk) 1999-06-11
US5587380A (en) 1996-12-24
IL113818A0 (en) 1995-08-31
AP8900155A0 (en) 1990-01-31
CN1052306A (zh) 1991-06-19
IL114019A0 (en) 1995-10-31
FI955941A (fi) 1995-12-11
IE893894L (en) 1990-06-07
LV10442B (en) 1995-08-20
EP0727212A2 (en) 1996-08-21
DK613289A (da) 1990-06-08
CN1115756A (zh) 1996-01-31
DK199900903A (da) 1999-06-24
CN1066720C (zh) 2001-06-06
NO941211L (no) 1990-06-08
AU5195696A (en) 1996-07-04
HU896444D0 (en) 1990-02-28
DD292250A5 (de) 1991-07-25
AP164A (en) 1992-01-12
IE80711B1 (en) 1998-12-16
EP0727214A2 (en) 1996-08-21
KR0145308B1 (ko) 1998-07-15
IL111627A (en) 1997-06-10

Similar Documents

Publication Publication Date Title
FI955939A0 (fi) Farmaseuttisesti aktiivisia CNS-yhdisteitä
DK0535034T3 (da) Farmaceutisk aktive benzoquinazolinforbindelser
IT1217573B (it) Benzammidi sostituite farmacologicamente attive
IT1229231B (it) Aminoimidazopiridine farmacologicamente attive
IT1173196B (it) Composti imidazopiridinici farmacologicamente attivi
SE8902170D0 (sv) Therapeutically active compounds
ZA899327B (en) Pharmaceutically active cns compounds
ITMI921865A1 (it) Glicerofosfoderivati farmacologicamente attivi
GB8918893D0 (en) Pharmacologically active cns compounds
IT8224221A0 (it) Composti farmaceuticamente attivi
GB8908561D0 (en) Pharmaceutically active cns compounds
AU639216C (en) Pharmaceutically active CNS compounds
GB8805811D0 (en) Pharmaceutically active compounds
SE8902584D0 (sv) New active compounds
IT1173197B (it) Composti imidazopiridinici farmacologicamente attivi
IT1173199B (it) Composti imidazopiridinici farmacologicamente attivi
SE9201338D0 (sv) New active compounds
SE9202553D0 (sv) New active compounds ii
GB8715274D0 (en) Pharmaceutically active compounds
GB8719717D0 (en) Pharmaceutically active compounds
GB8725540D0 (en) Pharmaceutically active compounds
GB8708234D0 (en) Pharmaceutically active compounds